The present disclosure relates generally to a composition for inhibiting the foreign body response to an implantable device and an implantable device that comprises the composition. The disclosure also relates to methods for preparing a device for implantation in a subject.

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Disclosed herein are bi- and tri-functional fusion proteins comprising two or more of an activin antagonist domain, a TOPβ antagonist domain, and an immune checkpoint antagonist domain. In addition, the disclosure provides methods of treating cancer, a tumor, a pre-neoplastic disorder, a hyperproliferative disorder, or a dysplastic disorder comprising administering a bi- or tri-functional fusion protein comprising two or more of an activin antagonist domain, a TOPβ antagonist domain, and an immune checkpoint antagonist domain. Optionally, such methods further comprise administering an additional active agent or supportive therapy for treating the cancer, a tumor, a pre-neoplastic disorder, a hyperproliferative disorder, or a dysplastic disorder.

Disclosed herein are bi- and tri-functional fusion proteins comprising two or more of an activin antagonist domain, a TOPβ antagonist domain, and an immune checkpoint antagonist domain. In addition, the disclosure provides methods of treating cancer, a tumor, a pre-neoplastic disorder, a hyperproliferative disorder, or a dysplastic disorder comprising administering a bi- or tri-functional fusion protein comprising two or more of an activin antagonist domain, a TOPβ antagonist domain, and an immune checkpoint antagonist domain. Optionally, such methods further comprise administering an additional active agent or supportive therapy for treating the cancer, a tumor, a pre-neoplastic disorder, a hyperproliferative disorder, or a dysplastic disorder.

The present invention relates to therapeutic uses of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, and long-acting conjugates thereof for liver disease.

In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

Disclosed are methods of treating metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), and Type II diabetes. In some examples, the method includes administration of an effective amount of a (pro)renin receptor (PRR) antagonist to a subject in need thereof, such as a patient at risk of acquiring or afflicted with NAFLD, NASH and/or Type II diabetes, to prevent, inhibit, and/or reduce one or more signs or symptoms associated with NAFLD, NASH and/or Type II diabetes, such as by reducing the severity of liver steatosis.

The present invention relates to chimeric antigen receptors (CARs) specific to ICAM-1 comprising I domain of the (XL subunit of human lymphocyte function-associated antigen 1 (LFA-1). The invention particularly relates to CARs comprising human I domains having different affinities (1 mM to 1 nM Kd) to ICAM-1. CAR T cells comprising human I domain having a low affinity (1 to 200 μM Kd) to ICAM-1 can avoid targeting healthy tissues with basal ICAM-1 expression while simultaneously exhibiting increased potency and long-term efficacy against tumor tissues with high ICAM-1 expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human I domain to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing ICAM-1 and kill the cancer cells.